{
  "docId": "019de076-87a3-715f-b988-6da9cfb3fd56",
  "docSlug": "560176b410a72a6b2e67af5dd2a20758",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 33,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Includes study design parameters (NST002) and key clinical outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/10",
  "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56",
  "deckJsonHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56.json",
  "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.76,
        "x": 0.21,
        "y": 0.7
      },
      "kind": "callout",
      "text": "These results led NeuroSense to commence a Phase 2b clinical study, using an improved new extended-release formulation of PrimeC",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "006d7462-9c6c-4f3b-96c6-d046636c4ff1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.73,
        "x": 0.24,
        "y": 0.33
      },
      "kind": "diagram",
      "text": "Well tolerated, no drug related SAEs; Reduced functional and respiratory deterioration; Significant changes in ALS-related biomarkers",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7485ebb-010b-4e9d-937c-500fa1ee4ece",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.18,
        "x": 0.03,
        "y": 0.28
      },
      "kind": "list",
      "text": "NST002, 15 patients, Open-Label, Intermediate formulation of PrimeC, 12-month dosing, Clinic visit every 3 months, Phone visit every 1.5 months, Location: Tel Aviv Sourasky Medical Center",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b66c06d-c85a-42ad-8c3f-535a6a714e19",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "PrimeC Met Primary Endpoints and Exploratory Endpoints in Phase 2a Study",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7bb3b66-55b9-46dd-9981-95a8d9df81ba",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 6,
      "beatId": "34d973c9-414c-4e7d-9b2b-216172775550",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}